AbbVie Inc. (ABBV) is set to report its Q1 2026 earnings on April 29, 2026. The pharmaceutical giant faces investor scrutiny as it continues navigating patent cliffs and competitive pressures in the drug manufacturing sector. With a market cap of $360.2 billion, ABBV remains a major player in healthcare. The company’s recent stock performance shows a 2.26% decline, trading at $203.67. Meyka AI rates ABBV with a grade of B+, reflecting mixed fundamentals. This earnings recap examines how ABBV’s upcoming results compare to historical performance and what they mean for shareholders.
AbbVie Earnings Performance Trend
AbbVie has demonstrated consistent earnings beats over the past four quarters, showing resilience despite market headwinds. The company’s recent earnings history reveals a pattern of outperformance relative to analyst expectations.
Q4 2025 Results
In the most recent quarter ending February 6, 2026, ABBV reported EPS of $2.71, beating the estimate of $2.65 by $0.06 per share. Revenue came in at $16.618 billion versus the estimated $16.413 billion, representing a $205 million beat. This marks the fourth consecutive quarter of earnings outperformance.
Three-Quarter Comparison
Looking back further, Q3 2025 showed EPS of $2.97 against an estimate of $2.88, beating by $0.09. Revenue hit $15.423 billion versus $15.029 billion estimated. Q2 2025 delivered EPS of $2.46 versus $2.38 expected, with revenue of $13.343 billion against $12.927 billion projected. These consistent beats suggest strong operational execution and effective cost management across the pharmaceutical portfolio.
Revenue Trends and Pharmaceutical Portfolio Strength
AbbVie’s revenue trajectory shows modest growth despite patent expiration challenges affecting key products. The company’s diversified drug portfolio continues generating solid top-line results across multiple therapeutic areas.
Revenue Growth Pattern
Quarterly revenues have ranged from $13.3 billion to $16.6 billion over the past year. The most recent quarter’s $16.618 billion represents the highest revenue in this period. Year-over-year revenue growth stands at 3.71%, indicating steady expansion. This growth is particularly noteworthy given the competitive pressures in immunology and oncology markets where ABBV operates.
Product Portfolio Performance
AbbVie’s core products including HUMIRA, SKYRIZI, RINVOQ, and IMBRUVICA continue driving revenue. The company’s transition from HUMIRA biosimilar competition to newer immunology treatments appears to be progressing. Gross profit margins remain strong at 73.3%, reflecting pricing power and manufacturing efficiency in the pharmaceutical sector.
Stock Price Movement and Technical Outlook
ABBV’s stock has experienced recent weakness, declining 2.26% to $203.67 as of the latest data. Technical indicators suggest mixed momentum heading into the earnings announcement. The stock trades below its 50-day and 200-day moving averages, indicating downward pressure.
Current Technical Position
The RSI stands at 43.71, indicating neither overbought nor oversold conditions. MACD shows negative momentum with a reading of -2.72. The stock’s 52-week range spans from $168.54 to $244.81, with current price near the lower end of recent trading. Volume has declined to 4.39 million shares versus the 7.07 million average, suggesting reduced trading interest.
Price Targets and Analyst Consensus
Analyst consensus remains constructive with 19 buy ratings and 8 hold ratings. The stock’s P/E ratio of 86.3 appears elevated relative to historical norms, reflecting market expectations. Meyka’s price forecasts suggest potential upside, with yearly targets around $237 and five-year projections near $322.
Financial Health and Valuation Metrics
AbbVie’s financial position shows solid cash generation capabilities, though balance sheet metrics warrant attention. The company maintains strong operational cash flow supporting its dividend and capital allocation strategy.
Cash Flow and Profitability
Operating cash flow per share reaches $10.69, while free cash flow per share stands at $10.50. The company’s dividend yield of 3.24% remains attractive for income investors. Net profit margin of 6.91% reflects pharmaceutical industry norms. However, the company carries significant debt with a debt-to-equity ratio of -21.06, indicating negative equity on the balance sheet.
Valuation Assessment
The price-to-sales ratio of 6.04 and enterprise value-to-sales of 7.07 suggest premium valuation. Interest coverage of 5.77x provides adequate debt servicing capacity. Meyka AI’s B+ grade reflects balanced risk-reward, considering strong cash generation against elevated leverage and valuation multiples in the current market environment.
Final Thoughts
AbbVie enters its Q1 2026 earnings announcement with a track record of consistent beats across the past four quarters. The company’s EPS and revenue have outperformed analyst expectations, demonstrating operational strength despite patent cliff pressures. However, recent stock weakness and elevated valuation multiples suggest investors are pricing in execution risks. With a market cap of $360.2 billion and Meyka AI’s B+ rating, ABBV remains a quality healthcare holding for dividend-focused investors. The upcoming earnings will be critical in confirming whether the company can sustain its outperformance trend and justify current valuations in a competitive pharmaceutical landscape.
FAQs
Did AbbVie beat earnings estimates in recent quarters?
Yes, ABBV beat earnings estimates in all four recent quarters. Q4 2025 showed EPS of $2.71 versus $2.65 estimate. Q3 delivered $2.97 versus $2.88. Q2 reported $2.46 versus $2.38. This consistent outperformance demonstrates strong operational execution.
What is AbbVie’s current stock price and recent performance?
ABBV trades at $203.67, down 2.26% recently. The stock is below its 50-day and 200-day moving averages. Year-to-date performance shows an 8.81% decline. However, the 12-month return is positive at 20.45%, reflecting longer-term strength.
What does Meyka AI’s B+ grade mean for ABBV?
Meyka AI rates ABBV with a B+ grade, suggesting a BUY recommendation. This reflects balanced fundamentals with strong cash generation and dividend yield offset by elevated valuation multiples and balance sheet leverage concerns.
How does AbbVie’s dividend compare to other healthcare stocks?
ABBV’s dividend yield of 3.24% is attractive for income investors. The company pays $6.74 per share annually. Strong free cash flow of $10.50 per share supports dividend sustainability and capital allocation flexibility.
What are the main risks to AbbVie’s earnings outlook?
Key risks include HUMIRA patent cliff competition, elevated debt levels, and premium valuation multiples. The P/E ratio of 86.3 is elevated. Patent expirations and biosimilar competition could pressure future revenue growth and margins.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)